The Future of IPRs & Bio-Pharmaceutical Innovation from The Global South
•
0 likes•78 views
Presentation at Changing Nature of Innovation Conference, May 2021, Ahmedabad University & CTIER, India
Report
Share
Report
Share
Download to read offline
Recommended
Innovation in life sciences
This report, commissioned by Dubai Science Park, explores the success of emerging markets in the life sciences industry and identifies strategic lessons for countries seeking to nurture their own life sciences sector.
Indo uk seminar
The document discusses the evolution and growth of India's biotechnology sector. Some key points:
- India has emerged as a dominant player in biotechnology, growing at 30-35% annually and becoming the 12th largest destination globally.
- The sector has grown from a small beginning 25 years ago when the Department of Biotechnology was established, to over 400 companies today employing hundreds of thousands.
- Indian biotech companies have developed drugs for diseases like cancer and diabetes and produce vaccines at significantly lower costs than international markets.
- The government has strongly supported the sector through funding, institutions, and a supportive regulatory environment. However, the regulatory process remains complex.
- India has strengths in human resources
Sm project
The document analyzes the biotechnology industry in India using Porter's Five Forces framework. It finds that the threat of new entrants and competitive rivalry within the industry are low due to high capital requirements and specialized expertise needed. The threat of substitute products and bargaining power of suppliers are also low. However, the bargaining power of customers is medium as some drugs have substitutes and customers are fragmented with a few influential buyers.
Bioindustry in Korea
The document discusses Korea's bioindustry and policies to promote its development. It outlines Korea's status in the global bioindustry, which has significant growth potential. While Korea has advanced biotechnology capabilities, its investment, industrial structure and global competitiveness still lag behind major economies. The vision is for Korea to become a leading bioeconomy by 2015. Key policy tasks include pursuing essential R&D, developing regional bioindustry clusters, replacing the petrochemical industry with biochemistry, vitalizing biotech businesses through various supports, and developing human resources in the field.
Is 2013 An Inflexion Point for Indian Healthcare Innovation
This document discusses whether 2013 marks an inflection point for healthcare innovation in India. It outlines several developments in 2013, including changes to patent laws regarding generic drugs. It questions whether these developments provide incentives for domestic Indian firms to innovate, and whether they help or hurt start-up companies. The document also examines implications for capacity building in other countries and concerns about the quality issues and reputations of some Indian firms. In conclusion, it suggests stakeholders will determine the future direction of healthcare innovation in India.
Challenges to indian bt industry
This document discusses the challenges facing the Indian biotechnological sector. It outlines that India has over 300 registered biotech companies but the sector is still in a nascent stage. Some key challenges include a lack of venture capital funding, weak entrepreneurial skills, and a risk-averse industry culture. Strengthening intellectual property protections and improving collaboration between research and industry will help drive future growth of the important but developing Indian biotech sector.
Creating Biosimilar Capabilities in Indian Pharma
This document discusses the transformation of the global biopharmaceutical industry from small-molecule chemistry drugs to large-molecule biological drugs due to advances in basic science. It focuses on the implications for the Indian bio-pharmaceutical industry. Analysis shows Indian firms have weak innovation and science capabilities for large molecules. Firm interviews revealed issues with human capital, competition, and regulation. Econometric analysis of regional drug demand in India found that domestic firms can produce more, charge lower prices than MNCs, and early movers gain market share through greater variety. The industry needs more investment in bio-science human capital and resolution of regulatory uncertainty to succeed in developing large molecule drugs.
Bio-Pharma: China 2010 - 2020
The document provides an overview of opportunities for big pharma companies in China from 2010 to 2020. It discusses trends of increasing foreign investment and virtual integration models. Cost reduction through production in China will drive future strategies, along with pursuing the large Chinese market and revenues. Innovation and R&D are migrating to China to access the large talent pool and lower costs of clinical trials. Virtual partnership models will become more common as companies extend their value chains without full ownership.
Recommended
Innovation in life sciences
This report, commissioned by Dubai Science Park, explores the success of emerging markets in the life sciences industry and identifies strategic lessons for countries seeking to nurture their own life sciences sector.
Indo uk seminar
The document discusses the evolution and growth of India's biotechnology sector. Some key points:
- India has emerged as a dominant player in biotechnology, growing at 30-35% annually and becoming the 12th largest destination globally.
- The sector has grown from a small beginning 25 years ago when the Department of Biotechnology was established, to over 400 companies today employing hundreds of thousands.
- Indian biotech companies have developed drugs for diseases like cancer and diabetes and produce vaccines at significantly lower costs than international markets.
- The government has strongly supported the sector through funding, institutions, and a supportive regulatory environment. However, the regulatory process remains complex.
- India has strengths in human resources
Sm project
The document analyzes the biotechnology industry in India using Porter's Five Forces framework. It finds that the threat of new entrants and competitive rivalry within the industry are low due to high capital requirements and specialized expertise needed. The threat of substitute products and bargaining power of suppliers are also low. However, the bargaining power of customers is medium as some drugs have substitutes and customers are fragmented with a few influential buyers.
Bioindustry in Korea
The document discusses Korea's bioindustry and policies to promote its development. It outlines Korea's status in the global bioindustry, which has significant growth potential. While Korea has advanced biotechnology capabilities, its investment, industrial structure and global competitiveness still lag behind major economies. The vision is for Korea to become a leading bioeconomy by 2015. Key policy tasks include pursuing essential R&D, developing regional bioindustry clusters, replacing the petrochemical industry with biochemistry, vitalizing biotech businesses through various supports, and developing human resources in the field.
Is 2013 An Inflexion Point for Indian Healthcare Innovation
This document discusses whether 2013 marks an inflection point for healthcare innovation in India. It outlines several developments in 2013, including changes to patent laws regarding generic drugs. It questions whether these developments provide incentives for domestic Indian firms to innovate, and whether they help or hurt start-up companies. The document also examines implications for capacity building in other countries and concerns about the quality issues and reputations of some Indian firms. In conclusion, it suggests stakeholders will determine the future direction of healthcare innovation in India.
Challenges to indian bt industry
This document discusses the challenges facing the Indian biotechnological sector. It outlines that India has over 300 registered biotech companies but the sector is still in a nascent stage. Some key challenges include a lack of venture capital funding, weak entrepreneurial skills, and a risk-averse industry culture. Strengthening intellectual property protections and improving collaboration between research and industry will help drive future growth of the important but developing Indian biotech sector.
Creating Biosimilar Capabilities in Indian Pharma
This document discusses the transformation of the global biopharmaceutical industry from small-molecule chemistry drugs to large-molecule biological drugs due to advances in basic science. It focuses on the implications for the Indian bio-pharmaceutical industry. Analysis shows Indian firms have weak innovation and science capabilities for large molecules. Firm interviews revealed issues with human capital, competition, and regulation. Econometric analysis of regional drug demand in India found that domestic firms can produce more, charge lower prices than MNCs, and early movers gain market share through greater variety. The industry needs more investment in bio-science human capital and resolution of regulatory uncertainty to succeed in developing large molecule drugs.
Bio-Pharma: China 2010 - 2020
The document provides an overview of opportunities for big pharma companies in China from 2010 to 2020. It discusses trends of increasing foreign investment and virtual integration models. Cost reduction through production in China will drive future strategies, along with pursuing the large Chinese market and revenues. Innovation and R&D are migrating to China to access the large talent pool and lower costs of clinical trials. Virtual partnership models will become more common as companies extend their value chains without full ownership.
Passing the healthcare innovation torch: from medicinal chemistry, though bio...
In the middle of the 20th Century, pharmaceutical companies were highly respected and patients depended on their physicians to make healthcare decisions. Drugs were a key part of a physician’s ‘toolkit’.
As we entered the era of the blockbuster drugs, most were small molecules made by chemical synthesis, but biotechnology was starting to emerge as a possible source of new therapeutics. Meanwhile, direct-to-consumer pharmaceutical advertising began to empower patients.
Fast forward to today, and we see pharmaceutical companies suffering degraded reputations and values, patients further empowered by the Internet and social media, and average life expectancies increased by a decade. Digital health technologies are poised to explode and the top 10 pharmaceuticals by sales will soon all be biologicals!
Australia-India: Combining Technology and Entrepreneurship to Innovate
This is the full text of the speech given by Dr. Kiran Mazumdar Shaw at the Australian National University, as part of the K.R. Narayanan Oration series on the 2nd of March, 2015. She spoke about building India-Australia high-tech business cooperation through start-ups.The K R Narayanan Oration Series at the Australia South Asia Research Centre in The Australian National University has been devoted to in-depth examination of this important issue by leading experts.
Challenges to indian biotech industry
The document summarizes the current state of the biotechnology sector in India, including its challenges and future potential. It notes that while India has over 300 biotech companies, the sector is still nascent. Key challenges include a lack of collaboration between research and industry, limited venture capital funding, and an inefficient patent system. However, India has strengths like human resources, biodiversity, and a large domestic market that could support future growth if these challenges are addressed. The future of Indian biotech may involve strengthening international partnerships and regulatory frameworks to better compete globally.
Dr. ta presentatio
This document summarizes the challenges facing the pharmaceutical research industry in India. It notes that while India has a large, low-cost workforce and regulatory framework to support pharmaceutical research, no new drug molecules have been developed domestically. The key challenges include high costs and failure rates in clinical trials, regulatory hurdles, concerns over side effects, and low productivity. Stakeholders across academia, industry and government must work together to strengthen education in interdisciplinary fields, promote intellectual property awareness, simplify regulations, and invest in research to help overcome these challenges and enable India to develop new drug molecules.
Biotechnology and India
Market insight report on Biotechnology in India covers products, technologies and services used in the Indian Biotechnology Industry. The report studies the Bio Pharma, Herbal Drugs, Bioservices and Bioindustrial markets in detail. Market estimations and predictions are illustrated by sector and by technology. Major Pharmaceutical, Bio Fuels, Bioinformatics companies and Contract Research Organizations serving the industry are also covered in the report. Information related to recent product releases, product developments, partnerships, collaborations, and mergers and acquisitions is covered in the report. An Indian perspective is presented along 44 exclusive graphically represented exhibits. Business profiles of 100 major companies are discussed in the report. The report serves as a guide to Indian Biotechnology industry, as it covers more than 300 companies that are engaged in biotechnology R&D, discovery, testing and supply of products and services.
Clinical Research In India
1) The document summarizes the state of clinical research in India, including the growth of the domestic and global clinical trials market in India, drivers of industry change, and India's strengths that make it an attractive location for outsourcing clinical research.
2) Key points discussed include India having a large, diverse population and strong technical skills that help accelerate patient recruitment for clinical trials compared to other countries. Costs of conducting clinical research in India are also much lower.
3) Challenges discussed include the need to further streamline regulatory processes, improve site infrastructure and staff training, and ensure strong data privacy protections to gain client confidence in outsourcing to India.
Bio similar- An opportunities or challenge for Indian Company
1. The global biosimilars market is expected to grow significantly in the coming years due to various drivers such as patent expiries of major biologics and increasing cost containment pressures.
2. Indian companies are well positioned in the biosimilars space due to their established low-cost manufacturing capabilities and expertise in biologics. Key players in India include Dr. Reddy's, Biocon, Cipla and Intas.
3. Developing biosimilars presents several challenges including high development costs, complex clinical trials and unclear regulatory guidelines. Indian companies strategy involves partnerships for cost-effective development and leveraging domestic capabilities and emerging markets for growth.
Developing a Globally Competitive Singaporean Life Science Industry
This paper seeks to explore the potential opportunities which Singapore can explore to fulfill its key economic objectives amidst global and regional developments within the life science industry and in the process develop Singapore-domiciled companies into viable players on the global stage.
Global Sourcing in Pharma
This presentation was made in Pharmasource Munich 2012 and covers the aspects of Pharma API and Intermediate sourcing. The presentation covers the following sub topics
1. How the changing structure of the Pharma industry is affecting ingredients sourcing
2. Are India and China still the places to go ( and for how long) – does the Cost - Benefit stack –up?
3. Supplier Innovation and Potential gains
4. Analyzing the Asian Pharma market –
a generics hub with a competitive skill base
i may be contacted at gurmeetsingh144@hotmail.com
Biocon's Eureka Moment - Mint Asia
1) Alzumab, an antibody developed by Biocon Ltd to treat psoriasis, showed promising results in clinical trials, effectively treating a patient's psoriasis within 8 weeks.
2) Alzumab works through the Th17 immune pathway and has the potential to treat over 100 autoimmune diseases. It was launched in India to treat psoriasis in August 2013.
3) Biocon's development of Alzumab was a breakthrough for the company and Indian innovation, as it was developed through a decade-long process and may establish credibility for Indian clinical research.
Health profits before people
The document discusses intellectual property rights (IPR) and the pharmaceutical industry. It notes that while IPR are meant to foster innovation, they can also limit access to medicines and raise prices. The document examines issues around IPR, pricing, access to medicines, and incentives for research and development. It provides background on epidemics like polio, malaria, and cholera. The document analyzes how IPR impact the pharmaceutical industry, including in India, and notes challenges in balancing IPR with public health concerns.
Biotech & Pharma Market July 2009
The document discusses opportunities in the Indian pharmaceutical and biotechnology sectors. It outlines 8 subsectors: pharmaceuticals, biopharma, contract research organizations, industrial enzymes, agribiotech, bioinformatics, diagnostics, and lab supplies. The core pharmaceutical industry focuses on small molecule drugs and generics. The biotech industry includes bio-pharma, agriculture, bioinformatics and is growing at 30% annually. The Indian pharma/biotech market was estimated at $18 billion in 2008-2009 and is projected to continue strong growth across subsectors.
Pharmacy - Arewarding Carerer (INDIA)
This document discusses career opportunities and emerging areas in the pharmacy profession in India. It outlines various career paths in areas like manufacturing, community pharmacy, hospitals, clinical research, academics, and more. Emerging sectors discussed include contract research and manufacturing services, diagnostics, medical devices, biotechnology, intellectual property law, information technology services, and novel drug delivery systems. The document emphasizes that while there are many opportunities, there is a shortage of professionals with the right skills and attitudes to meet growing demand. It encourages students to identify their interests and start developing in-demand skills from their undergraduate studies.
Biotech& biomed.2012.presentation3
The document discusses various topics related to biotechnology and biomedicine from a global perspective. It provides an overview of biotechnology applications, major biotechnology companies worldwide with the US dominating, and achievements in biotechnology in countries like India, China, and the US. It also summarizes developments in areas like medical biotechnology, biomedical engineering, genomics, tissue engineering, and future directions of biomedicine involving concepts like lab-on-a-chip and nanosensors.
Agribiotech R&D in Private sector
The document discusses public-private partnerships (PPP) in agribiotech research and development in India. It notes that while the seed industry in India is growing, private sector investment in R&D remains low compared to countries like the US. It identifies several challenges with current PPP models, including a lack of mutual trust between public and private sectors and a lack of infrastructure and financial incentives. It recommends strengthening engagement between industries and public institutions to facilitate more partnerships and collaboration in agribiotech innovation.
Carrier in chemistry
This document provides an overview of career opportunities in chemistry after completing a BSc in Chemistry in India. It discusses options for higher studies such as MScs and PhDs in various fields of chemistry. It also outlines career paths in industries like pharmaceuticals, chemicals, agriculture, oil and gas. The document highlights the growth of the Indian chemical and pharmaceutical industries. It provides statistics on the size and exports of these industries. It also discusses the job roles available in areas like manufacturing, quality control, research and regulatory affairs and the skills required for these roles. In conclusion, it emphasizes the strong potential for employment and education in chemistry-related fields in India over the next 15 years.
Seminar slides - biotech - ukieri
The document discusses the future trajectories of the Indian biotech industry. It notes that while the industry is growing, it still represents a small fraction of the global biotech market. The author examines how Indian firms oscillate between leapfrogging established technologies and discovering capabilities through self-learning. The challenges facing firms include navigating the patent cliff faced by large pharma and commercializing academic research. The role of entrepreneurs, public science, and government policy are also discussed. Overall, the future remains bright if the ecosystem and institutions continue evolving to support the vibrancy and capabilities seen in Indian biotech scientists and startups.
Telangana Life Sciences Policy
The document provides an overview of the life sciences sector in Telangana, India. It discusses how Hyderabad emerged as a leader in bulk drugs and vaccines due to the establishment of organizations like IDPL in the 1960s. This sparked growth of the private pharmaceutical industry. It also highlights the role of organizations like ICRISAT, CCMB, IICT, CDFD and NIN in developing an R&D ecosystem. Key initiatives like BioAsia and Pharmexcil helped link local players to the global biotech community. The life sciences clusters in Hyderabad, Bangalore and Mumbai-Pune account for over 80% of India's life sciences manufacturing and R&D. Hyderabad has
The Pharma 2020 series : PWC Pharma-success-strategies
The Pharma 2020 series
The Pharmaceutical industry's long successful strategy of placing big bets on a few molecules, promoting them heavily and turning them into blockbusters worked well for many years, but its R&D productivity has now plummeted and the environment’s changing. PwC believes that seven major trends are reshaping the marketplace:
Source of info:
http://www.pwc.com/gx/en/pharma-life-sciences/pharma2020/index.jhtml#
Healthcare Outlook 2015 Global & APAC
This document provides an overview and outlook of the global healthcare industry in 2015, including key trends and statistics. Some of the main points covered include:
- Global harmonization is increasing in areas like regulations and standards to reduce costs and complexity. Biologics are growing in importance.
- The aging global population and rise of non-communicable diseases is driving growth, particularly in Asia. Countries are focusing on value-based pricing and cost containment.
- Total global healthcare revenue was estimated at $1.568 trillion in 2015, with pharmaceuticals accounting for over half. Asia's revenue was estimated at $353 billion.
- Generics are facing increased pressure and opportunity as developed countries look to contain costs
Strategy Analytics Webinar - For IIMA's ePGD-ABA Program
This is a quick overview on the role of analytics, insights and big-data as it redefines competitive advantage and strategic management in modern corporations.
EUODA and Early Stage Venture Capital Investment in Biopharmaceutical Industry
1) The study finds that the EU Orphan Drug Act (EUODA) increased early stage venture capital investments in biopharmaceutical subfields by 3-5% relative to control subfields, translating to about 2000 new early-stage investments.
2) EUODA also had regulatory spillover effects, helping US venture capitalists more than EU venture capitalists and increasing cross-border venture investing.
3) While EUODA lowered syndication activity for early stage investments, it did not decrease the average amount raised per investment round.
4) EUODA improved exit performance for treated firms, resulting in more initial public offerings than acquisitions and no significant effect on bankruptcies.
More Related Content
Similar to The Future of IPRs & Bio-Pharmaceutical Innovation from The Global South
Passing the healthcare innovation torch: from medicinal chemistry, though bio...
In the middle of the 20th Century, pharmaceutical companies were highly respected and patients depended on their physicians to make healthcare decisions. Drugs were a key part of a physician’s ‘toolkit’.
As we entered the era of the blockbuster drugs, most were small molecules made by chemical synthesis, but biotechnology was starting to emerge as a possible source of new therapeutics. Meanwhile, direct-to-consumer pharmaceutical advertising began to empower patients.
Fast forward to today, and we see pharmaceutical companies suffering degraded reputations and values, patients further empowered by the Internet and social media, and average life expectancies increased by a decade. Digital health technologies are poised to explode and the top 10 pharmaceuticals by sales will soon all be biologicals!
Australia-India: Combining Technology and Entrepreneurship to Innovate
This is the full text of the speech given by Dr. Kiran Mazumdar Shaw at the Australian National University, as part of the K.R. Narayanan Oration series on the 2nd of March, 2015. She spoke about building India-Australia high-tech business cooperation through start-ups.The K R Narayanan Oration Series at the Australia South Asia Research Centre in The Australian National University has been devoted to in-depth examination of this important issue by leading experts.
Challenges to indian biotech industry
The document summarizes the current state of the biotechnology sector in India, including its challenges and future potential. It notes that while India has over 300 biotech companies, the sector is still nascent. Key challenges include a lack of collaboration between research and industry, limited venture capital funding, and an inefficient patent system. However, India has strengths like human resources, biodiversity, and a large domestic market that could support future growth if these challenges are addressed. The future of Indian biotech may involve strengthening international partnerships and regulatory frameworks to better compete globally.
Dr. ta presentatio
This document summarizes the challenges facing the pharmaceutical research industry in India. It notes that while India has a large, low-cost workforce and regulatory framework to support pharmaceutical research, no new drug molecules have been developed domestically. The key challenges include high costs and failure rates in clinical trials, regulatory hurdles, concerns over side effects, and low productivity. Stakeholders across academia, industry and government must work together to strengthen education in interdisciplinary fields, promote intellectual property awareness, simplify regulations, and invest in research to help overcome these challenges and enable India to develop new drug molecules.
Biotechnology and India
Market insight report on Biotechnology in India covers products, technologies and services used in the Indian Biotechnology Industry. The report studies the Bio Pharma, Herbal Drugs, Bioservices and Bioindustrial markets in detail. Market estimations and predictions are illustrated by sector and by technology. Major Pharmaceutical, Bio Fuels, Bioinformatics companies and Contract Research Organizations serving the industry are also covered in the report. Information related to recent product releases, product developments, partnerships, collaborations, and mergers and acquisitions is covered in the report. An Indian perspective is presented along 44 exclusive graphically represented exhibits. Business profiles of 100 major companies are discussed in the report. The report serves as a guide to Indian Biotechnology industry, as it covers more than 300 companies that are engaged in biotechnology R&D, discovery, testing and supply of products and services.
Clinical Research In India
1) The document summarizes the state of clinical research in India, including the growth of the domestic and global clinical trials market in India, drivers of industry change, and India's strengths that make it an attractive location for outsourcing clinical research.
2) Key points discussed include India having a large, diverse population and strong technical skills that help accelerate patient recruitment for clinical trials compared to other countries. Costs of conducting clinical research in India are also much lower.
3) Challenges discussed include the need to further streamline regulatory processes, improve site infrastructure and staff training, and ensure strong data privacy protections to gain client confidence in outsourcing to India.
Bio similar- An opportunities or challenge for Indian Company
1. The global biosimilars market is expected to grow significantly in the coming years due to various drivers such as patent expiries of major biologics and increasing cost containment pressures.
2. Indian companies are well positioned in the biosimilars space due to their established low-cost manufacturing capabilities and expertise in biologics. Key players in India include Dr. Reddy's, Biocon, Cipla and Intas.
3. Developing biosimilars presents several challenges including high development costs, complex clinical trials and unclear regulatory guidelines. Indian companies strategy involves partnerships for cost-effective development and leveraging domestic capabilities and emerging markets for growth.
Developing a Globally Competitive Singaporean Life Science Industry
This paper seeks to explore the potential opportunities which Singapore can explore to fulfill its key economic objectives amidst global and regional developments within the life science industry and in the process develop Singapore-domiciled companies into viable players on the global stage.
Global Sourcing in Pharma
This presentation was made in Pharmasource Munich 2012 and covers the aspects of Pharma API and Intermediate sourcing. The presentation covers the following sub topics
1. How the changing structure of the Pharma industry is affecting ingredients sourcing
2. Are India and China still the places to go ( and for how long) – does the Cost - Benefit stack –up?
3. Supplier Innovation and Potential gains
4. Analyzing the Asian Pharma market –
a generics hub with a competitive skill base
i may be contacted at gurmeetsingh144@hotmail.com
Biocon's Eureka Moment - Mint Asia
1) Alzumab, an antibody developed by Biocon Ltd to treat psoriasis, showed promising results in clinical trials, effectively treating a patient's psoriasis within 8 weeks.
2) Alzumab works through the Th17 immune pathway and has the potential to treat over 100 autoimmune diseases. It was launched in India to treat psoriasis in August 2013.
3) Biocon's development of Alzumab was a breakthrough for the company and Indian innovation, as it was developed through a decade-long process and may establish credibility for Indian clinical research.
Health profits before people
The document discusses intellectual property rights (IPR) and the pharmaceutical industry. It notes that while IPR are meant to foster innovation, they can also limit access to medicines and raise prices. The document examines issues around IPR, pricing, access to medicines, and incentives for research and development. It provides background on epidemics like polio, malaria, and cholera. The document analyzes how IPR impact the pharmaceutical industry, including in India, and notes challenges in balancing IPR with public health concerns.
Biotech & Pharma Market July 2009
The document discusses opportunities in the Indian pharmaceutical and biotechnology sectors. It outlines 8 subsectors: pharmaceuticals, biopharma, contract research organizations, industrial enzymes, agribiotech, bioinformatics, diagnostics, and lab supplies. The core pharmaceutical industry focuses on small molecule drugs and generics. The biotech industry includes bio-pharma, agriculture, bioinformatics and is growing at 30% annually. The Indian pharma/biotech market was estimated at $18 billion in 2008-2009 and is projected to continue strong growth across subsectors.
Pharmacy - Arewarding Carerer (INDIA)
This document discusses career opportunities and emerging areas in the pharmacy profession in India. It outlines various career paths in areas like manufacturing, community pharmacy, hospitals, clinical research, academics, and more. Emerging sectors discussed include contract research and manufacturing services, diagnostics, medical devices, biotechnology, intellectual property law, information technology services, and novel drug delivery systems. The document emphasizes that while there are many opportunities, there is a shortage of professionals with the right skills and attitudes to meet growing demand. It encourages students to identify their interests and start developing in-demand skills from their undergraduate studies.
Biotech& biomed.2012.presentation3
The document discusses various topics related to biotechnology and biomedicine from a global perspective. It provides an overview of biotechnology applications, major biotechnology companies worldwide with the US dominating, and achievements in biotechnology in countries like India, China, and the US. It also summarizes developments in areas like medical biotechnology, biomedical engineering, genomics, tissue engineering, and future directions of biomedicine involving concepts like lab-on-a-chip and nanosensors.
Agribiotech R&D in Private sector
The document discusses public-private partnerships (PPP) in agribiotech research and development in India. It notes that while the seed industry in India is growing, private sector investment in R&D remains low compared to countries like the US. It identifies several challenges with current PPP models, including a lack of mutual trust between public and private sectors and a lack of infrastructure and financial incentives. It recommends strengthening engagement between industries and public institutions to facilitate more partnerships and collaboration in agribiotech innovation.
Carrier in chemistry
This document provides an overview of career opportunities in chemistry after completing a BSc in Chemistry in India. It discusses options for higher studies such as MScs and PhDs in various fields of chemistry. It also outlines career paths in industries like pharmaceuticals, chemicals, agriculture, oil and gas. The document highlights the growth of the Indian chemical and pharmaceutical industries. It provides statistics on the size and exports of these industries. It also discusses the job roles available in areas like manufacturing, quality control, research and regulatory affairs and the skills required for these roles. In conclusion, it emphasizes the strong potential for employment and education in chemistry-related fields in India over the next 15 years.
Seminar slides - biotech - ukieri
The document discusses the future trajectories of the Indian biotech industry. It notes that while the industry is growing, it still represents a small fraction of the global biotech market. The author examines how Indian firms oscillate between leapfrogging established technologies and discovering capabilities through self-learning. The challenges facing firms include navigating the patent cliff faced by large pharma and commercializing academic research. The role of entrepreneurs, public science, and government policy are also discussed. Overall, the future remains bright if the ecosystem and institutions continue evolving to support the vibrancy and capabilities seen in Indian biotech scientists and startups.
Telangana Life Sciences Policy
The document provides an overview of the life sciences sector in Telangana, India. It discusses how Hyderabad emerged as a leader in bulk drugs and vaccines due to the establishment of organizations like IDPL in the 1960s. This sparked growth of the private pharmaceutical industry. It also highlights the role of organizations like ICRISAT, CCMB, IICT, CDFD and NIN in developing an R&D ecosystem. Key initiatives like BioAsia and Pharmexcil helped link local players to the global biotech community. The life sciences clusters in Hyderabad, Bangalore and Mumbai-Pune account for over 80% of India's life sciences manufacturing and R&D. Hyderabad has
The Pharma 2020 series : PWC Pharma-success-strategies
The Pharma 2020 series
The Pharmaceutical industry's long successful strategy of placing big bets on a few molecules, promoting them heavily and turning them into blockbusters worked well for many years, but its R&D productivity has now plummeted and the environment’s changing. PwC believes that seven major trends are reshaping the marketplace:
Source of info:
http://www.pwc.com/gx/en/pharma-life-sciences/pharma2020/index.jhtml#
Healthcare Outlook 2015 Global & APAC
This document provides an overview and outlook of the global healthcare industry in 2015, including key trends and statistics. Some of the main points covered include:
- Global harmonization is increasing in areas like regulations and standards to reduce costs and complexity. Biologics are growing in importance.
- The aging global population and rise of non-communicable diseases is driving growth, particularly in Asia. Countries are focusing on value-based pricing and cost containment.
- Total global healthcare revenue was estimated at $1.568 trillion in 2015, with pharmaceuticals accounting for over half. Asia's revenue was estimated at $353 billion.
- Generics are facing increased pressure and opportunity as developed countries look to contain costs
Similar to The Future of IPRs & Bio-Pharmaceutical Innovation from The Global South (20)
Passing the healthcare innovation torch: from medicinal chemistry, though bio...
Passing the healthcare innovation torch: from medicinal chemistry, though bio...
Australia-India: Combining Technology and Entrepreneurship to Innovate
Australia-India: Combining Technology and Entrepreneurship to Innovate
Bio similar- An opportunities or challenge for Indian Company
Bio similar- An opportunities or challenge for Indian Company
Developing a Globally Competitive Singaporean Life Science Industry
Developing a Globally Competitive Singaporean Life Science Industry
The Pharma 2020 series : PWC Pharma-success-strategies
The Pharma 2020 series : PWC Pharma-success-strategies
More from Chirantan Chatterjee
Strategy Analytics Webinar - For IIMA's ePGD-ABA Program
This is a quick overview on the role of analytics, insights and big-data as it redefines competitive advantage and strategic management in modern corporations.
EUODA and Early Stage Venture Capital Investment in Biopharmaceutical Industry
1) The study finds that the EU Orphan Drug Act (EUODA) increased early stage venture capital investments in biopharmaceutical subfields by 3-5% relative to control subfields, translating to about 2000 new early-stage investments.
2) EUODA also had regulatory spillover effects, helping US venture capitalists more than EU venture capitalists and increasing cross-border venture investing.
3) While EUODA lowered syndication activity for early stage investments, it did not decrease the average amount raised per investment round.
4) EUODA improved exit performance for treated firms, resulting in more initial public offerings than acquisitions and no significant effect on bankruptcies.
Berkeley Info-camp Talk - Ethical Scaling - Chatterjee
Talk on Ethical Scaling of Digital Platforms at UC Berkeley School of Information (https://berkeley-infocamp.org/)
Access, Innovation & Public Policy in Healthcare Markets ICICI Bank Chair L...
The document summarizes past research conducted by Chirantan Chatterjee. It discusses research on balancing access to healthcare and innovation incentives, the welfare effects of differential drug pricing in India, cartels in the Indian drug market, the role of physicians in irrational drug use in India, and the diffusion of universal healthcare coverage in India influenced by spatial peer effects. The ongoing research covers topics like the market response to pandemics, experiments on women's risks in buying fairness creams, and the effects of price controls in the Indian malaria drug market. The document acknowledges funding support and concludes by thanking the audience and posing open questions.
Towards Healthy Billions BMGF talk - Chatterjee-circulation
This document provides a summary of Chirantan Chatterjee's background and research interests. It outlines his educational and professional background, including receiving a PhD in applied economics from Carnegie Mellon University. It then summarizes some of his past research papers covering topics like pharmaceutical markets in India and the US, universal health coverage, and the role of physicians in India. It lists some of his current research projects and notes his openness to collaborating on new projects related to health issues in India like mental health, health technology, and public drug policy.
Round Table on IP & Access to Medicines
1) The document discusses balancing access to medicines with innovation, noting that one size may not fit all situations given contingencies in therapeutic markets.
2) It presents perspectives from Adam Smith, Muhammad Yunus, and Hart & Zingales on firms and entrepreneurs having non-profit motives and needing to consider social dimensions.
3) Alternative approaches to patents are discussed, such as priority review vouchers, advance market commitments, and innovation prizes, as well as the roles of venture capital and complementary health infrastructure.
4) The document concludes by framing the issue as responsible firms needing to converge with responsible social planners to find welfare-maximizing solutions, as depicted in a two-by-two matrix
Panel Moderator & Discussant - Paul Janssen TB Symposium (CSIR-IMTECH)
This document summarizes a panel discussion on tuberculosis. It provides an overview of tuberculosis trends globally from 2009-2015, noting both improvements and ongoing challenges. Specifically, while prevalence is decreasing, every 18 seconds someone still dies from TB. Further, only a small portion of those in need received two newer, more effective medicines to treat drug-resistant TB. The document also discusses the high costs of treating multi-drug resistant TB and questions around access to new treatments, including how public health and the roles of innovators, policymakers, and providers can help achieve global tuberculosis treatment targets by 2025 in countries like India.
The Future of Innovationism
This document discusses the concept of innovationism. It defines innovation as the introduction of new goods, improved production methods, new markets, new supply sources, or better organization as defined by economist Joseph Schumpeter. It explores who innovates, including the public and private sectors, large firms and entrepreneurs, individuals and teams. Models of innovation discussed include the linear model, the relationship between firm size and innovation, Pasteur's Quadrant, democratizing innovation, and the location of innovation. The document also addresses innovationism for organizations through tools like innovation audits and metrics, and platforms to incentivize innovation. It wraps up with a discussion of responsible innovationism and the economic history of innovation.
The Flute, A Peltzman Effect & Indian Healthcare
The document discusses healthcare in India and the concept of the Peltzman Effect. It introduces the story of three characters - Bob, Anne, and Carla - to represent different groups in Indian healthcare. It then discusses different philosophical views of justice as they relate to healthcare and notes that no single system can satisfy all views. The document outlines producer-side, consumer-side, and regulator-side Peltzman Effects in Indian healthcare. It proposes monitoring evidence to learn and maintain flexibility to hybridize approaches as seen in examples from Mass General, Hiranandani, Portea/Practo, and Novartis/MHE. The presentation concludes by noting there will be more discussion on these topics in an
Disruption ahoy! cc-inma2015
The document discusses the concept of disruption in business. It defines disruption as a theory of business failure caused by new entrants or technologies. Disruption can occur through lower-cost business models or new markets. The document notes that disruption is closely related to industry evolution. It provides examples of how core competencies, competitive advantages, and organizational forms are changing for businesses facing disruption. Finally, it raises questions about how incumbent firms should respond to disruption and the challenges they may face.
The Economics of China
China has experienced rapid economic growth over recent decades, transitioning from a largely agricultural economy to an industrial and commercial powerhouse. However, this growth has also created new challenges for China relating to inequality, environmental degradation, and regional economic disparities. As China's economy continues to evolve, it remains to be seen whether the country can manage these issues and maintain economic momentum, or if weaknesses could potentially constrain future growth.
The Economics of Ideas & Asia
This document discusses the economics of ideas, focusing on non-rivalrous and excludable goods like ideas. It introduces the concepts of rivalrous vs. non-rivalrous goods and how ideas are non-rivalrous but can be made excludable. This gives rise to increasing returns and imperfect competition in markets for ideas. The document also presents a basic Romer-style model of endogenous growth driven by increasing returns from new ideas. It questions whether growth will continue indefinitely and discusses challenges to US growth from factors like demographics, debt, and environmental constraints.
Global Pharmaceutical R&D - Some Political Economy & Public Policy Considerat...
Global Pharmaceutical R&D - Some Political Economy & Public Policy Considerat...Chirantan Chatterjee
Invited Lecture for Canadian Institutes of Health Research & Karnataka Health Promotion Trust's International Infectious Disease & Global Health Training Program
Strategic Thinking for Hospital CXOs
This document discusses various frameworks for strategic thinking for hospital CXOs. It summarizes Porter's 5 forces model and the resource-based view of the firm. It also discusses the importance of resources, capabilities, and focusing strategy. Disruptive innovation and examples from the Indian pharmaceutical industry are provided. Overall, the key points are that both industry structure and a firm's unique resources influence strategy, and strategy must consider focusing capabilities and disruptions in the industry.
Indian Economy & Business (Skyped Lecture U-Tokyo Graduate Students)
This document discusses India's economic growth and transformation. It notes that while India was growing rapidly and seen as competing with China, its growth has slowed in recent years. It attributes this partly to global slowdown but mainly to structural issues as "the low hanging fruits being gone." It argues that India now needs structural transformation, including addressing sub-national heterogeneity and institutional voids. It highlights some positive factors like a young workforce, entrepreneurship, and sunrise industries, but says more needs to be done in areas like governance, education, and policy consistency to help facilitate India's continued economic development.
Quality (not dirty) medicines - The Way Ahead for Indian Pharma
This document summarizes a presentation given by Chirantan Chatterjee at an IIM-Bangalore workshop on improving the consumer interface of pharmaceutical and private healthcare in India. The presentation discusses several issues with India's pharmaceutical industry and regulatory system, including having different standards for domestic and export markets, a lack of evidence-based regulation, and differences across regions. It provides examples of initiatives in Gujarat that have helped improve traceability, transparency and oversight. The presentation concludes by calling for the country to address existing issues and shortcomings rather than being complacent, in order to better protect public health.
Trade Models & Asian Economic Growth
1) The document discusses various international trade models including absolute advantage, comparative advantage, and the Heckscher-Ohlin model.
2) It examines the Heckscher-Ohlin model in depth, outlining its key ideas including the Stolper-Samuelson theorem, Rybczynski theorem, and factor price equalization.
3) The Heckscher-Ohlin model predicts that countries will export goods that intensively use their abundant factors of production and import goods that intensively use their scarce factors.
Lewis Model & Dual Economies in Asia
The document discusses Arthur Lewis's model of dual economies and its application to Asia. The Lewis model describes an economy with two sectors - a subsistence agricultural sector and a higher productivity manufacturing sector. Workers transfer from the agricultural sector to the manufacturing sector as wages equalize, driving economic growth. Eventually, a "Lewis turning point" is reached where no new workers are available and wages begin rising in both sectors, slowing growth. The document argues China may be approaching this turning point and examines implications for other Asian economies like India. It also discusses assumptions and extensions of the Lewis model over time.
On Market-Boundaries in Pharmaceutical Sector (at Competition Commission of I...
On Market-Boundaries in Pharmaceutical Sector (at Competition Commission of I...Chirantan Chatterjee
The document discusses thinking creatively about product markets in the pharmaceutical industry. It begins by outlining some key considerations, such as the role of physicians and regulators. It then discusses different market structures and how defining the appropriate market boundary is important but challenging. The document emphasizes that market definition depends on the specific question and data available. It provides examples of how to conceptualize product markets using classification codes like ATC and Ephrama at different levels of granularity.More from Chirantan Chatterjee (19)
Strategy Analytics Webinar - For IIMA's ePGD-ABA Program
Strategy Analytics Webinar - For IIMA's ePGD-ABA Program
EUODA and Early Stage Venture Capital Investment in Biopharmaceutical Industry
EUODA and Early Stage Venture Capital Investment in Biopharmaceutical Industry
Berkeley Info-camp Talk - Ethical Scaling - Chatterjee
Berkeley Info-camp Talk - Ethical Scaling - Chatterjee
Access, Innovation & Public Policy in Healthcare Markets ICICI Bank Chair L...
Access, Innovation & Public Policy in Healthcare Markets ICICI Bank Chair L...
Towards Healthy Billions BMGF talk - Chatterjee-circulation
Towards Healthy Billions BMGF talk - Chatterjee-circulation
Panel Moderator & Discussant - Paul Janssen TB Symposium (CSIR-IMTECH)
Panel Moderator & Discussant - Paul Janssen TB Symposium (CSIR-IMTECH)
Global Pharmaceutical R&D - Some Political Economy & Public Policy Considerat...
Global Pharmaceutical R&D - Some Political Economy & Public Policy Considerat...
Indian Economy & Business (Skyped Lecture U-Tokyo Graduate Students)
Indian Economy & Business (Skyped Lecture U-Tokyo Graduate Students)
Quality (not dirty) medicines - The Way Ahead for Indian Pharma
Quality (not dirty) medicines - The Way Ahead for Indian Pharma
On Market-Boundaries in Pharmaceutical Sector (at Competition Commission of I...
On Market-Boundaries in Pharmaceutical Sector (at Competition Commission of I...
Recently uploaded
Natural birth techniques - Mrs.Akanksha Trivedi Rama University
Natural birth techniques - Mrs.Akanksha Trivedi Rama UniversityAkanksha trivedi rama nursing college kanpur.
Natural birth techniques are various type such as/ water birth , alexender method, hypnosis, bradley method, lamaze method etcAzure Interview Questions and Answers PDF By ScholarHat
Azure Interview Questions and Answers PDF By ScholarHat
Top five deadliest dog breeds in America
Thinking of getting a dog? Be aware that breeds like Pit Bulls, Rottweilers, and German Shepherds can be loyal and dangerous. Proper training and socialization are crucial to preventing aggressive behaviors. Ensure safety by understanding their needs and always supervising interactions. Stay safe, and enjoy your furry friends!
CACJapan - GROUP Presentation 1- Wk 4.pdf
Macroeconomics- Movie Location
This will be used as part of your Personal Professional Portfolio once graded.
Objective:
Prepare a presentation or a paper using research, basic comparative analysis, data organization and application of economic information. You will make an informed assessment of an economic climate outside of the United States to accomplish an entertainment industry objective.
Your Skill Boost Masterclass: Strategies for Effective Upskilling
Your Skill Boost Masterclass: Strategies for Effective UpskillingExcellence Foundation for South Sudan
Strategies for Effective Upskilling is a presentation by Chinwendu Peace in a Your Skill Boost Masterclass organisation by the Excellence Foundation for South Sudan on 08th and 09th June 2024 from 1 PM to 3 PM on each day.Types of Herbal Cosmetics its standardization.
Physiology and chemistry of skin and pigmentation, hairs, scalp, lips and nail, Cleansing cream, Lotions, Face powders, Face packs, Lipsticks, Bath products, soaps and baby product,
Preparation and standardization of the following : Tonic, Bleaches, Dentifrices and Mouth washes & Tooth Pastes, Cosmetics for Nails.
How to Add Chatter in the odoo 17 ERP Module
In Odoo, the chatter is like a chat tool that helps you work together on records. You can leave notes and track things, making it easier to talk with your team and partners. Inside chatter, all communication history, activity, and changes will be displayed.
Executive Directors Chat Leveraging AI for Diversity, Equity, and Inclusion
Let’s explore the intersection of technology and equity in the final session of our DEI series. Discover how AI tools, like ChatGPT, can be used to support and enhance your nonprofit's DEI initiatives. Participants will gain insights into practical AI applications and get tips for leveraging technology to advance their DEI goals.
How to Manage Your Lost Opportunities in Odoo 17 CRM
Odoo 17 CRM allows us to track why we lose sales opportunities with "Lost Reasons." This helps analyze our sales process and identify areas for improvement. Here's how to configure lost reasons in Odoo 17 CRM
Hindi varnamala | hindi alphabet PPT.pdf
हिंदी वर्णमाला पीपीटी, hindi alphabet PPT presentation, hindi varnamala PPT, Hindi Varnamala pdf, हिंदी स्वर, हिंदी व्यंजन, sikhiye hindi varnmala, dr. mulla adam ali, hindi language and literature, hindi alphabet with drawing, hindi alphabet pdf, hindi varnamala for childrens, hindi language, hindi varnamala practice for kids, https://www.drmullaadamali.com
clinical examination of hip joint (1).pdf
described clinical examination all orthopeadic conditions .
Assessment and Planning in Educational technology.pptx
In an education system, it is understood that assessment is only for the students, but on the other hand, the Assessment of teachers is also an important aspect of the education system that ensures teachers are providing high-quality instruction to students. The assessment process can be used to provide feedback and support for professional development, to inform decisions about teacher retention or promotion, or to evaluate teacher effectiveness for accountability purposes.
The simplified electron and muon model, Oscillating Spacetime: The Foundation...
Discover the Simplified Electron and Muon Model: A New Wave-Based Approach to Understanding Particles delves into a groundbreaking theory that presents electrons and muons as rotating soliton waves within oscillating spacetime. Geared towards students, researchers, and science buffs, this book breaks down complex ideas into simple explanations. It covers topics such as electron waves, temporal dynamics, and the implications of this model on particle physics. With clear illustrations and easy-to-follow explanations, readers will gain a new outlook on the universe's fundamental nature.
Recently uploaded (20)
Natural birth techniques - Mrs.Akanksha Trivedi Rama University
Natural birth techniques - Mrs.Akanksha Trivedi Rama University
Azure Interview Questions and Answers PDF By ScholarHat
Azure Interview Questions and Answers PDF By ScholarHat
Your Skill Boost Masterclass: Strategies for Effective Upskilling
Your Skill Boost Masterclass: Strategies for Effective Upskilling
Pride Month Slides 2024 David Douglas School District
Pride Month Slides 2024 David Douglas School District
Executive Directors Chat Leveraging AI for Diversity, Equity, and Inclusion
Executive Directors Chat Leveraging AI for Diversity, Equity, and Inclusion
Liberal Approach to the Study of Indian Politics.pdf
Liberal Approach to the Study of Indian Politics.pdf
How to Manage Your Lost Opportunities in Odoo 17 CRM
How to Manage Your Lost Opportunities in Odoo 17 CRM
Assessment and Planning in Educational technology.pptx
Assessment and Planning in Educational technology.pptx
The simplified electron and muon model, Oscillating Spacetime: The Foundation...
The simplified electron and muon model, Oscillating Spacetime: The Foundation...
The Future of IPRs & Bio-Pharmaceutical Innovation from The Global South
- 1. The Future of IPRs & Bio-Pharmaceutical Innovation from The Global South Chirantan Chatterjee IIMA & Hoover Institution, Stanford University www.chirantanchatterjee.com Changing Nature of Innovation Conference Ahmedabad University and CTIER May 2021
- 2. Of a previous pathogenic outbreak discovery in 2010
- 3. India a hotbed of AMR, yet Carbapenem sales go up!
- 4. Why Is it that We are Not generating New Antibiotics?
- 5. Some Answers from a Field Trip in Summer 2007-2008 - Agglomeration Economies. - Where is the Scientist-Entrepreneur? (Bayh Dole Act & Pasteur’s Quadrant). - Even pre-Covid no Patient Venture Capital. - Human Capital Issues. - An extinct taste for biology while focusing on chemistry in the last 5 decades. - Regulatory flipflops & flight of entrepreneurs to locations like Singapore. - Other locations rising (S-Korea, Bangladesh among others). - India and perhaps global south, more and more an incrementally innovative society (than a radically innovative society). - Services & tech innovation takes precedence over a life-science economy.
- 6. Where to Next for the Industry? - Biosimilars (requires science, clinical trials, regulation) - Preventive Innovation than Therapeutic Innovation (Medical Devices startups like Janacare, Xcyton Diagnostics, Achira et al.) - Drug Repurposing (Beyond Lopinavir). - R&D versus non R&D Alliances (the Roche-Cipla efforts). - Structural Shifts in Innovation Ecosystem Required - Taking advantage of the mRNA Disruption as other countries catch up. - Forming R&D Consortiums ala the Japanese? - Differding, E. (2017). The Drug Discovery and Development Industry in India—Two Decades of Proprietary Small‐Molecule R&D. ChemMedChem, 12(11), 786-818.
- 7. Global R&D Situation 2021 - India appears, more expected
- 8. Global R&D Situation 2021 - The Molnupiravir Effect
- 9. Global R&D Situation 2021 - Oncology Dominates
- 10. Global R&D Situation 2021 - Changing Nature of Innovation
- 11. Global R&D Situation 2021 Role of Global South/India in Flourishing Markets for Technology?
- 12. Global R&D Situation 2021 Role of Global South/India in Flourishing Markets for Technology?
- 13. Push & Pull Regulatory Shifts - Local & Global
- 14. Covid-19 Patent Waiver, RCEP, LDC TRIPS transition, Geo-Politics et al.
- 15. Thank You - Health & Wealth - Tough New World & Trade-offs Ahead.. ■ “There is nothing I fear more than waking up without a program that will help me bring a little happiness to those with no resources, those who are poor, illiterate, and ridden with terminal disease.” - Nelson Mandela.